Okay, so Hims & Hers, the telehealth company that wants to sell you everything from hair loss pills to, uh, "personalized" treatments, is now sniffing around Novo Nordisk's Wegovy? Seriously? This is like letting the fox guard the henhouse, except the fox is a venture-capital-fueled startup and the henhouse is, well, your health.
The "Personalized" Problem
Let's be real: Hims & Hers is all about subscriptions and pushing product. They beat revenue expectations, sure, but earnings fell short. See the disconnect? They're not making more money because they're providing better care; they're making more money because they're getting more people hooked on recurring charges. And now they want to add Wegovy, a powerful weight loss drug, to the mix? What could possibly go wrong?
I mean, think about it. Wegovy ain't some over-the-counter supplement. It has potential side effects, requires careful monitoring, and should be prescribed by a doctor who actually knows you, not some algorithm-driven telehealth service that's probably more concerned with its churn rate than your long-term well-being.
But hey, who needs nuanced medical advice when you can get "personalized" treatments delivered straight to your door? Personalized according to what, exactly? The data they scraped from your Facebook profile? The answers you gave to a five-minute online questionnaire? Give me a break.
Stocks Up, Trust Down
Of course, the stock jumped 6% after hours. Wall Street loves this stuff. Growth! Disruption! But what about, you know, ethics? What about responsible healthcare? I guess those don't show up on a quarterly earnings report.
And look at the other companies making moves. Palantir, raking in cash from government contracts... Clorox, cleaning up literally and figuratively after a messy year... Upwork, connecting freelancers to gigs in a world where full-time employment is becoming a distant memory... It's all part of the same dystopian picture, ain't it? Companies profiting off of our anxieties, our insecurities, and our increasingly precarious economic situations. According to Stocks making the biggest moves after hours: Palantir, Hims & Hers Health, Clorox and more, these companies are seeing significant stock fluctuations.
I'm not saying Hims & Hers is evil, per se. But this whole situation just feels… icky. It feels like another step toward a world where healthcare is just another commodity to be bought and sold, where your well-being is secondary to a company's bottom line. And honestly, I don't know about you, but that's not a world I want to live in.
The Unanswered Question
The article mentions subscriber growth fueling revenue, but it doesn't say what those subscribers are actually being prescribed. Are they all getting the same handful of "personalized" treatments, regardless of their individual needs? Are doctors being pressured to prescribe certain drugs over others? And how is Hims & Hers ensuring that patients are properly monitored for side effects and potential complications? These are questions that need answers, and fast.
